Almonertinib as Upfront Treatment for Uncommon EGFR Mutation Harboring Non-Small-Cell Lung Cancer Patients: A Multicenter, Open-Label, Phase II Trial
Clinical trial NCT04553887 · UNKNOWN
Trial details
- NCT number
- NCT04553887
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-11-01
- Primary completion
- 2023-05-01
- Enrollment
- 53
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.